v3.26.1
Acquisitions - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 5 Months Ended 6 Months Ended
Mar. 24, 2025
Mar. 23, 2025
Jan. 16, 2025
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Disclosure of detailed information about business combination [line items]                  
Investment ownership percentage             21.40%    
Goodwill             $ 9,259   $ 9,256
Cash paid for the acquisition             $ 0 $ 568  
LENSAR, Inc.                  
Disclosure of detailed information about business combination [line items]                  
Total consideration (up to)   $ 430              
Aurion Biotech, Inc.                  
Disclosure of detailed information about business combination [line items]                  
Investment ownership percentage   40.30%              
Ownership percentage in subsidiary 99.00%                
Aurion Biotech, Inc.                  
Disclosure of detailed information about business combination [line items]                  
Percentage of outstanding shares acquired 58.70%                
Total acquisition date fair value of consideration $ 486                
Previously-held commercialization rights in intangible assets 36                
Cash paid at closing 522                
Goodwill 175                
Cash paid for the acquisition 496                
Previously-held investment in associated company 334                
Equity interest remeasurement fair value gain         $ 136        
Direct acquisition cost $ 2                
Reduction in net income from acquired business       $ 17          
Cylite Pty Ltd.                  
Disclosure of detailed information about business combination [line items]                  
Percentage of outstanding shares acquired     91.20%            
Total acquisition date fair value of consideration                 123
Cash paid at closing                 78
Goodwill     $ 90           90
Cash paid for the acquisition     72            
Contingent consideration, maximum     10            
Previously-held investment in associated company     14           $ 14
Equity interest remeasurement fair value gain         $ 6        
Direct acquisition cost     $ 1            
Reduction in net income from acquired business           $ 8